Botox and Trulicity are two well-known medications included in the next round of Medicare price negotiations scheduled for this year.
This will be the third round of price negotiations between Medicare and pharmaceutical manufacturers.
The Inflation Reduction Act of 2022 authorized the Medicare program to negotiate with drug makers for the first time.
Medicare, the world’s largest buyer of prescription drugs, must negotiate prices for at least 60 medications by 2029.
Drugs included in this year’s negotiations are among the most expensive provided through Medicare. They treat diseases ranging from diabetes to chronic migraines, HIV, and cancer.
The 15 drugs are Anoro Ellipta, Biktarvy, Botox and Botox Cosmetic, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Trulicity, Verzenio, Xeljanz and Xeljanz XR, and Xolair….
Botox and 14 Other Drugs to Be Negotiated by Medicare This Year
